Wegovy, Zepbound

The proposed buyout of contract drug manufacturer Catalent won’t raise competition concerns, the European Commission said.
Wegovy and other GLP-1 medications have become extremely popular over the past few years. Novo Nordisk (which makes both ...
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head ...
Drug manufacturer Eli Lilly says their drug Zepbound is more effective than Wegovy for long-term weight loss. Results from a ...
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo ...
As new research suggests those taking GLP-1 drugs have fewer hospitalisations for alcoholism, a leading specialist warns ...